The quality of the sequencing data generated in the laboratory has a direct impact on the accuracy and reliability of downstream bioinformatic results. Poor-quality or biased sequence data can reduce accuracy of de novo assembly, variant calling and estimates of microbial abundance, directly impacting organism identification, pathogen detection, outbreak analysis, and prediction of antimicrobial resistance.
The landscape of clinical microbiology and public health is evolving faster than ever. At BugSeq, we are continuously enhancing our platform to ensure laboratories have the most advanced, accurate, and rapid bioinformatics tools at their disposal. In the first quarter of 2026, we focused our efforts on four major areas: deepening our viral surveillance capabilities, optimizing our pipelines for the rapid turnaround of the new Illumina MiSeq i100, expanding our expert-curated Antimicrobial Resistance (AMR) databases, and seamlessly integrating with Oxford Nanopore’s EPI2ME Desktop environment.
Pathogen agnostic diagnostic assays, driven by metagenomic next-generation sequencing (mNGS), enable diagnosis and surveillance of pathogens unlike any other technology. However, a lack of bioinformatic frameworks and evidence to guide reporting thresholds has made the technology too complex for most labs. BugSeq’s latest innovation, BugID, brings intuitive, evidence-based thresholds within reach for your metagenomic assay.